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HYPOPHYSECTOMY was introduced for the treatment of cancer of the breast in
women by Pearson, Ray, West, Harrold, MacLean and Li (1954) and by Luft
and Olivecrona (1955). Only about 50 per cent of these cancers show a response,
the so-called hormone-dependent tumours. With these tumours it has been
found that a better response is obtained with complete removal of the pituitary
than with incomplete hypophysectomy, as the former causes the greater modifica-
tion of the hormone environment.
It is of concern in the management of patients submitted to hypophysectomy
that a satisfactory means of assessing completeness of hypophysectomy be used.
The methods used principally involve measurement ofpituitary hormone or target
organ hormone production, and gonadotrophins, adrenocortical function and
thyroid function are commonly measured (Baron and Gurling, 1960).
After hypophysectomy, patients are maintained on cortisone. They excrete
small quantities of 17-oxosteroids, which may be derived from the administered
cortisone, or from the adrenal cortex under the stimulus of ACTH from remnants
ofincompletely removed pituitary. To investigate this it is necessary to perform
differential analysis of the urinary 17-oxosteroids. The two 17-oxosteroid meta-
bolites of cortisone which are 11-oxoaetiocholanolone and 1l,8-hydroxyaetio-
cholanolone, (3a-hydroxy-5/3-androstane-11: 17-dione and 30c: 11,/-dihydroxy-5/J-
androstane-17-one) are readily separated from the major C11-deoxy-17-oxosteroids,
dehydroepiandrosterone, androsterone and aetiocholanolone, which are endo-
genous products.
Johnsen (1956) used this approach and published one excretion pattern of
17-oxosteroids from a patient with cancer of the breast, treated by hypophy-
sectomy. He claimed that the entire disappearance of androsterone is a reliable
sign of the completeness of hypophysectomy.
In the present work a method more refined than that used by Johnsen has been
applied to the study of 17-oxosteroid excretion in cases of women with cancer of
breast, to detect any change in their excretion pattern after hypophysectomy and
to try to establish whether or not hypophysectomy has been complete.
This paper is an enlargement on research already given in a Ph.D. thesis
(Khattab, 1956) and on the work of Holliday, Kellie and Wade (1958).
MATERIAL AND METHODS
All the patients who underwent hypophysectomy were suffering from carci-
noma of the breast with metastases. All but two cases were post-menopausal,
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or had been ovariectomized. Ofthe twelve patients so far studied, one underwent
pituitary stalk section (Case 7), the rest had surgical removal of the pituitary.
After an initial period in hospital for investigation and assessment, surgical
hypophysectomy was performed by the transfrontal approach and 7 5 mc of
198Au was inserted (as seeds) into the pituitary fossa (Baron, Gurling and Radley
Smith, 1958). Cortisone was given, in variable doses depending on the patient's
condition, to cover the operation and for maintenance. Thyroid replacement
therapy was given post-operatively.
Pre-operative and post-operative studies were performed on the urinary
17-oxosteroid excretion when cortisone was being given, and when possible post-
operatively and not receiving cortisone. The method adopted in this work was
the one published by Kellie and Wade (1957) which consisted of (a) extraction of
the steroid conjugates from the urine (which has no preservative), (b) hydrolysis
of the glucuronide and sulphate fractions independently, (c) gradient elution
chromatography on alumina, (d) estimation of individual steroids, (e) paper
chromatography and infra-red spectroscopy for identification ofsteroids whenever
possible.
RESULTS
Unique difficulties encountered during the processing of urines from patients with
cancer of the breast
In applying to urines from patients with cancer of the breast the method of
17-oxosteroid analysis already used satisfactorily with other urines, new problems
were encountered which made the evaluation of the results before and after
hypophysectomy very difficult. A primary cause of these problems was the low
output of total 17-oxosteroids and (after hypophysectomy) the polyuria which
made it necessary to process very large volumes of urine in order to obtain
measurable amounts of 17-oxosteroid. Excessive amounts of a red pigment
(presumably indigo red, Dobriner, Lieberman and Rhoads, 1948) present in many
fractions made it extremely difficult to get an accurate measure of the 17-oxo-
steroid content of the urines or the chromatographic fractions. Absorption at
520 ma in the Zimmermann reaction, which appeared to indicate 17-oxosteroid
content, was shown to be falsely high when the material was chromatographed on
paper for the purposes of identification. An example will illustrate these points.
Case 12. Analysis of a pre-hypophysectomy urine gave a total 17-oxosteroid
excretion of 4-2 mg. per 24 hours, 1-3 mg. as glucuronides and 2 9 mg. as sulphates.
Chromatography of the 17-oxosteroids from the glucuronide fraction gave a final
accuracy of 56 0 per cent, whilst from the 17-oxosteroids excreted as sulphates,
the accuracy after chromatography on alumina was only 8 per cent. From these
figures therefore the amount of steroid really excreted was 0 7 mg. as glucuronide
and 0*23 mg. as sulphate, a total of less than 1P0 mg. per 24 hours.
In other cases, chromatography on alumina gave apparently well-defined
peaks in recognisable positions, but paper chromatography failed to reveal the
presence of the expected steroids. Such has been the case even when readings
in the spectrophotometer showed maximum absorption at 520 m,u indicating,
as one might think, the presence of a 17-oxosteroid.
It is apparent therefore that the neutral steroid extracts obtained from the
urine of patients under discussion all contained pigment which produced, under
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the conditions of the Zimmermann reaction, the same colour as 17-oxosteroid.
The application of Allen's correction which assumes a linear background to the
spectrophotometer readings was not sufficient to eliminate this effect.
In general, however, on paper chromatograms the pigment had an R1 value
different from that of the 17-oxosteroids and did not interfere with the identifica-
tion of compounds or the interpretation of the results.
From a quantitative point of view, therefore, the figures obtained for 17-oxo-
steroid excretion lack precision, and emphasis has been placed largely on the
qualitative aspect of the results.
In older methods of steroid analysis separation of the neutral extract into
ketonic and non-ketonic fractions, by means of Girard's reagent T, was a standard
procedure, essential for satisfactory work. Milder methods of hydrolysis have,
generally speaking, made this step unnecessary since less pigment is produced
when hot acid hydrolysis is avoided.
In the present work on urines from hypophysectomised patients it was initially
considered that this step was unnecessary and almost all of the preliminary work
had been done before the difficulties inherent in the procedure were appreciated.
More reliable quantitative figures could possibly have been obtained if the Girard
separation had been applied to all urines instead of only to the very highly
pigmented fractions.
In those instances where a Girard separation was performed, the recovery of
17-oxosteroids agreed very closely with the results after chromatography on
alumina. For example the sulphate fraction from case 12, both pre- and post-
operative, was subjected to a Girard separation, after removal of an aliquot for
chromatography. The results are presented in Table I.
TABLE I
Percentage
accuracy after
17-oxosteroid mg. per 24 hr. Percentage chromatography
-,&,- - accuracy of material
Before Girard After Girard after Girard before Girard
Case 12 separation separation separation separation
Pre-op. . 2-9 0-23 * 8-0 . 8-0
Post-op. . 2-2 0-17 . 8-0 . 7-7
In presenting the quantitative results therefore two figures have been given
where possible.
(1) The 17-oxosteroid figure based on a direct Zimmermann determination.
(2) A corrected 17-oxosteroid figure based on the estimation of 17-oxosteroids
after chromatography on alumina.
The pre-operative figures for the 17-oxosteroid excretion obtained in these
cases of carcinoma of the breast are all very low, as found generally by other
workers. The results are presented in Table II.
Apart from case 9, the daily excretion barely exceeds 1-0 mg. This is
considerably below the lowest range of normal excretion. Most of the patients
were suffering from widespread malignant disease. A further possible reason for
low 17-oxosteroid excretion in patients with carcinoma of the breast is that they
may have destructive secondaries in the adrenals. It is notable however that no
matter how low the excretion both forms of conjugation are found; sometimes
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TABLE II
Z Total 17- 17-oxosteroid 17-oxosteroid Percentage Percentage
Case or oxosteroids glucuronides sulphates 17-oxosteroids 17-oxosteroids
No. C mg. per 24 hr. mg. per 24 hr. mg. per 24 hr. as glucuronides as sulphates
1 Z 1 90 0085 1 05 44-7 55*3
C 1-05 0-47 0*58
2 Z 1-30 0-55 0-7541852 C 0 86 0 36 0 50 418 582
3 Z 180 1825 0054 70*0 30.0
C 0-87 0-60 0-27
9 Z 8-80 7-30 1-5080911 C 6880 5750 130 809 191
10 Z 0 60 0.10 0 50 20-0 80 0
C 0-20 0-04 0-16
11 Z 2790 1 70 1-20 70-0 30-0 C 1-70 1-20 0-50
12 Z 4-20 1-30 2-90 75-7 24-3
C 0995 0-72 0*23
Z 17-oxosteroid figure based on a direct Zimmermann determination.
C 17-oxosteroid figure based on estimation of 17-oxosteroid after chromatography on alumina.
the sulphate fraction predominates. In spite of the low 17-oxosteroid excretion,
the chromatographic pattern of excretion remains substantially normal in so far
as the types of compound excreted are concerned. Other workers (e.g. Kellie,
1954) have shown that all the compounds present in the urines of normal indi-
viduals (Fig. 1) may be excreted by patients with carcinoma of the breast. The
claim that 1 l/3-hydroxyaetiocholanolone, a minor component of the 17-oxosteroid
fraction is significantly associated with neoplastic growth (Reifenstein, Homburger
and Dobriner, 1950) has been disproved (Kellie, 1955); the compound has been
found in the urine of all normal individuals examined. In the present series of
cases, paper chromatography revealed the presence of all expected compounds
pre-operatively. Ofthe 11-deoxy compounds, androsterone and aetiocholanolone
were always present, dehydroepiandrosterone was not detected in one case
(No. 10); but the amount of material available for chromatography was very
small.
Each of the four Cll-oxygenated 17-oxosteroids normally excreted was found
in every patient studied. The 17-oxosteroid excretion of these carcinomatous
patients does not differ quantitatively in any significant way from the results
reported by other workers. Nor does it differ in its constituents from normal
individuals which were analysed for comparative purposes (Fig. 2).
Effect of hypophysectomy on 17-oXosteroid excretion
Total 17-oxosteroid excretion after hypophysectomy is shown in Table III
(Uncorrected and corrected figures).
The figures for 17-oxosteroid are very similar to those obtained pre-hypophy-
sectomy. It must be remembered, however, that after hypophysectomy the
patients were receiving a maintenance dose of cortisone ; the excretion figures
therefore do not represent metabolites only of endogenous hormone secretion.
In all cases the presence of metabolites of cortisone was demonstrated by paper
chromatography.
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FIG. la, b. Distribution of 17-oxosteroids on chromatography of glucuronide and sulphate
fractions of normal urine. For methods see text.
D = dehydroepiandrosterone A = androsterone
E = aetiocholanolone And = an(drostenedione
11 0 = 11-oxo- 11 OH = JI fl-hydroxy-
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Biochemical evidence for the probable completeness or otherwise of hypo-
physectomy was obtained on the basis of a number of tests:
(1) Tests of thyroidfunction:
a. Basal metabolic rate.
b. Radioactive iodine tests.
(2) Excretion of total gonadotrophins.
(3) Induction of adrenal insufficiency (demonstrated by a fall in the urinary
excretion of 17-oxosteroids and 17-hydroxysteroids) on withdrawing cortisone.
CASE No.2
12- CARCINOMA of the
.E BREAST
Glucuronide fraction
a D
12- CACNMAo hA
110HA O
4- |11E unidentified
steroid
2 110A OE
0 20 40 60 80 100 120 140 160 180
ml. eluate
2a
D CASE No.2
12 CARCINOMA of the
BREAST
~io- Sulphate fraction
/8-
6
A
4 ~~~~~~~~~~~~~unidentified
steroid
E
2-
0 20 40 60 80 100 120 140 160 180
m7l. eluate
2b
FiG. 2a, b. Urinary oxosteroids in a patient with carcinoma of the breast, prehvpophysectomy
(see also legend to Fig. 1) The dotted peaks at the far left are unresolved diones.
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TABLE III
Total 17- 17-oxosteroid 17-oxosteroid
oxosteroids glucuronides sulphates
mg. per 24 hr. mg. per 24 hr. mg. per 24 hr
3-6 2-8 0 7
2 7 2-4 0 3
3-5 2 7 0-8
3.5 2*7 0 8
1-9 1.1 0.8
1.1 0-6 0*5
1.0 0 7 0-3
0 4 0 3 0-1
3.5 2*3 1-2
1-6 1-4 0-2
3-5 2-3 1-2
2-7 2-3 0-4
3-5 1b7 1-8
1-7 1-3 0-4
All material chromatographed on paper:
12 Z 3-2
C 0-8
1.0
0-6
2-2
0 2
Percentage
17-oxosteroids
as glucuronides
88-8
77-1
54-5
75*0
87-5
85-1
76-4
No analytical figure available
75 0
Z = 17-oxosteroid figure based on a direct Zinmmermann determination.
C = 17-oxosteroid figure based on estimation of 17-oxosteroid after chromatography on alumina.
On the basis of these four cases (No. 4, 5, 8 and 9) were judged to be incom-
pletely hypophysectomised. The 11-deoxy-17-oxosteroid excretion of these
patients after operation is shown in Table IV and qualitatively it does not differ
from the excretion pattern before hypophysectomy (Fig. 3). Each of the three
11-deoxy compounds was identified by paper chromatography.
TABLE IV.-Post-operative Incomplete Hypophysectomy
Case
Compound No. 4
Dehydroepiandrosterone . +
Androsterone . . +
Aetiocholanolone . +
Case Case Case
No. 5 No. 8 No. 9
+
+
±
+
+
In those cases where the operation was considered to be complete however,
different results were obtain (Table V).
TABLE V.-Post-operative Complete Hypophysectomy
Dehydroepiandrosterone
Pre-op. Post-op.
Androsterone
P ,o.Ps-p Pre-op. Post-op.
+ 0 . +
+ O . +
- +
+ 0 * +
+ 0 . +
+
+
+
Aetiocholanolone
_- I
Pre-op. Post-op.
* + +
* + +
+ ±
* + +
* + +
+ = Present
0 = Absent
= Insufficient steroid for confirmation.
z
Case or
No. C
4 z
C
5 z
C
6 Z
C
7 z
C
8 Z
C
9 z
C
10 Z
C
11 Z
C
Percentage
17-oxosteroids
as sulphates
11 2
22-9
4.5-5
25-0
12-5
14-9
23-6
25-0
Case
No.
6
7
10
11
12
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No dehydroepiandrosterone was found in the urine of any of these patients
post-operatively. On the other hand, all of them excreted aetiocholanolone and
androsterone (Fig. 4).
Pre-operatively four 11-oxygenated 17-oxosteroids were identified: 11-oxo-
androsterone, 11-oxoaetiocholanolone, 1lfl-hydroxyandrosterone and 11,8-
hydroxyaetiocholanolone. Post-operatively, with cortisone, J1-oxoaetiocholano-
lone and 11,8-hydroxyaetiocholanolone were detected in most cases. In a few
cases, in addition to these cortisone metabolites, 11-oxygenated androsterone
11OE CASE No. 5 12 CARCINOMA of the
E BREAST
10 POST-HYPOPHYSECTOMY
A MAINTAINED on CORTISONE
81 0 1 l lGlucuronide fraction
41 A|| 11OA 110HHA 110HE unidentified
A A Asteroid
m(.eluate
3a
3b
FIG. 3a- b. Urinary. oxosteroids-in a patient-with-careinoma- of the breast
after incomplete hypophysectomy (see also legend to Fig. 1).
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derivatives were excreted in small amounts: these are I-oxoandrosterone and
11,8-hydroxy-androsterone.
From these results two conclusions seem permissible:
(1) Dehydroepiandrosterone is not excreted in the urine after complete
hypophysectomy. (Patients shown by other biochemical tests to have had
12-
0 t10-
u' 8-
6-
t 4-
2-
20 40 60 80 100 120
ml. eluate
4a
0
qi
,)
0
V-.
140 160
80 100 120
tnm. eluate
4b
FIG. 4a, b. Urinary oxosteroids in a patient with carcinoma of the breast following complete
hypophysectomy (see also legend to Fig. 1).
Adr. = adrenosterone
The dotted peak to the left of A (glucuronide) was not a steroid.
350
O E CASE No. 11
CARCINOMA of the
BREAST
POST-HYPOPHYSECTOMY
MAINTAINED on CORTISONE
Glucuronide fraction
11 OH E
11 OHA 1 l\
.^.
I
: : E17-OXOSTEROID EXCRETION
incomplete hypophysectomy showed traces of dehydroepiandrosterone in the
urine.)
(2) Both androsterone and aetiocholanolone may continue to be excreted in
the urine after complete hypophysectomy.
DISCUSSION
The 17-oxosteroid excretion after hypophysectomy is diminished e.g. in case 9
it fell from 6*8 to 2-7 mg. per 24 hours; probably at least 1 mg. is due to the
administration of cortisone. In no case, however, did 17-oxosteroid excretion
fall to zero.
Aetiocholanolone and androsterone were found in all post-operative urines
whether or not cortisone was being administered, except in case 11, in which
neither was found when cortisone was stopped; neither of these two com-
pounds is believed to be a metabolite of cortisone. Johnsen (1956) states that
disappearance of androsterone may probably be taken as an indication of com-
plete hypophysectomy ; the results reported here do not agree with this view.
In contrast, dehydroepiandrosterone has not been found in any post-operative
urine specimen when hypophysectomy was complete. The biosynthesis of this
compound from cholesterol, acetate or other precursor by the adrenal is thought
to be dependent on the presence of adrenocorticotropic hormone (ACTH), secreted
by the hypophysis (Dorfman and Shipley, 1956). If, therefore, the hypophysis
is removed, the absence ofACTH should prevent the synthesis ofdehydroepiandro-
sterone. If that interpretation is correct, it follows that the synthesis of andro-
sterone and aetiocholanolone, or their precursors, by the adrenal is not wholly
dependent on the presence of ACTH, or that they arise from some other source.
In humans there are three sources of androgens; the adrenal cortex and the
testes in males, and the ovaries in females. All the patients in the present series
were post-menopausal (either naturally or artificially) so that the ovaries can be
eliminated as a source of androgens. (In women with functioning ovaries there
is as yet no reason to believe that this organ is an important source of androgens.)
None of the patients had had adrenalectomy, although it is possible that the
functional tissue in some, as in cases 8 and 10, may have been decreased through
metastatic invasion and destruction.
Dehydroepiandrosterone: This androgenic steroid arises in the adrenal cortex,
but its precursors are not yet known. It is largely metabolised to androsterone
and aetiocholanolone, but may also give rise to small amounts of other compounds
(Z5-androstene-3,/: 17/,-diol, z5-androstene-3,8: 16cc: 17,8-triol). Part of the
dehydroepiandrosterone is excreted in the urine as such.
An important intermediate in the production of both Cl9 and C21 compounds
by the adrenal is believed to be pregnenolone (z15-pregnen-3/l-ol-20-one) which
in turn is derived from cholesterol, and possibly other precursors (acetate, chole-
stenone). Pregnenolone may be converted into C19 or C21 compounds. Dehydro-
epiandrosterone may also arise directly from cholesterol.
It is postulated that ACTH is necessary to initiate the chain of events along
each pathway, but subsequent conversions are independent ofACTH. Iftherefore
the supply of ACTH to the adrenal is removed by hypophysectomy, then the
formation of dehydroepiandrosterone cannot take place.
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The facts elucidated by the present work can be explained by this hypothesis.
Thus, in those cases where hypophysectomy was judged incomplete, ACTH
could still be produced to initiate the conversion of a precursor to dehydroepi-
androsterone; this compound was in fact detected in the urine in these cases.
Conversely, in the completely hypophysectomised individuals, loss of ACTH
should lead to suppression of dehydroepiandrosterone formation; none was in
fact detected in the urine of these patients.
Androsterone and aetiocholanolone. Both these compounds are found in
the urine of normal women, whether pre-or post-menopausal, and are stated to be
of adrenal origin, or more correctly, to be metabolic products of compounds
secreted by the adrenal cortex. Thus dehydroepiandrosterone and 14-androstene-
3-17-dione, both of adrenocortical origin, have been shown to be metabolised to
and excreted as androsterone and aetiocholanolone. They may also arise from
17a-hydroxyprogesterone, and 17-hydroxy-11-desoxycorticosterone. This has
been shown by in vivo metabolism studies in humans (Gallagher, 1954; Fajans.
Louis and Conn, 1951), but the predominating stereoisomer is aetiocholanolone
with androsterone being produced in only minor amounts.
Since dehydroepiandrosterone is no longer produced by the adrenals after
hypophysectomy, then androsterone and aetiocholanolone cannot arise from
this source. The same argument also applies to the C21 precursors ofandrosterone
and aetiocholanolone if it is correct, as is postulated, that the C21 compounds
found in the adrenal arise from a precursor (pregnenolone) whose production
from, say, cholesterol is mediated by ACTH. It is contrary to all current ideas of
steroid metabolism to suggest that androsterone and aetiocholanolone might
arise from the metabolism of cortisone. No one has as yet succeeded in demon-
strating an increase in androsterone and aetiocholanolone excretion after the
administration of cortisone.
17-oxosteroid excretion in case 11 however could be interpreted by suggesting
that cortisone can give rise to 11-desoxy-17-oxosteroids. 17-oxosteroids were
estimated before hypophysectomy and after hypophysectomy during periods with
and without the administration of cortisone. The steroids excreted, identified
by paper chromatography, are shown in Table VI.
TABLE VI
Dehydroepi- Andro- Aetio-
Case 11 androsterone sterone cholanolone
Pre-operative + + +
Post-operative Cortisone 0 + . +
No cortisone 0 0 0
+ = present 0 absent
Whilst cortisone was being administered, androsterone and aetiocholanolone
were identified in urinary extracts. When cortisone was withdrawn, no 11 -deoxy-
17-oxosteroids could be identified. This single case however does not provide
sufficient evidence to make a dogmatic statement that cortisone gives rise to
1 -deoxy metabolites; the result suggests that further work should be done
along these lines.
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SU'MMARY
(1) A precise micro-method for the determination of total and fractionated
urinary 17-oxosteroids has been applied to study the effect of hypophysectomy
on the secretion of androgens in carcinoma of the breast in women.
(2) 17-Oxosteroid excretion in those women before hypophysectomy was low,
but qualitatively normal excretion patterns have been obtained.
(3) After complete hypophysectomy, there was a total disappearance of
dehydroepiandrosterone from the urine, but androsterone and aetiocholanolone
continued to be excreted.
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